Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxane plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
2008-003997-17Phase 3Terminated
- Sponsor
- GBG Forschungs
- Start
- Nov 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paclitaxel, docetaxel, bevacizumab and capecitabine in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Progression Free Survival. Started Nov 2008; status: terminated.
02
Drugs
paclitaxeldocetaxelbevacizumabcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003997-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003997-17.